Cipla, shares gained on Tuesday after the company announced commercial collaboration with S&D Pharma in the Czech Republic and Slovakia. This collaboration will enable Cipla to focus on its core therapy areas, while S&D Pharma will be the key partner for generics.

Under the collaboration, Cipla will be driving its respiratory product portfolio in both Czech Republic and Slovakia through a Cipla owned sales force team, managed by Cipla commercial head.

Shares of the company are trading at Rs 568.75, up Rs 5.35, or 0.95% at the Bombay Stock Exchange (BSE) on Tuesday at 10:42 a.m.

The scrip has touched an intra-day high of Rs 572.80 and low of Rs 566. The total volume of shares traded at the BSE is 71,712.